Nihon Kohden, a U.S. market leader in precision medical products and services, today unveiled its new Life Scope G9, a bedside monitor that provides comprehensive parameter observation and allows clinicians to quickly and easily customize the monitor to each patient regardless of health status or care setting. Created with the goal of improving outcomes and enhancing the patient experience, the multimodality Life Scope G9 is fully optimized for use in any clinical setting as part of Nihon Kohden’s premium-as-standard philosophy.
The full-featured Life Scope G9 offers inclusive monitoring capabilities, allowing clinicians to oversee and track a comprehensive set of parameters across care areas. When used in conjunction with Nihon Kohden’s BSM-1700 transport monitor, the Life Scope G9 continues to record data even during transport, which can be one of the most dangerous times in patient care.
“Every patient has the potential to take a turn for the worse when it’s least expected,” said Dr. Wilson P. Constantine, chief executive officer, Nihon Kohden America. “Because of this, we believe that every piece of equipment should include all features – both standard and premium – unlocked and ready to use at a moment’s notice. This philosophy was a guiding light in the development of the Life Scope G9, and will allow it to be used in the broadest range of acuity levels in the hospital.”
The monitor includes features that will help improve clinical outcomes, such as the ability to ensure patients are observed based on common metrics and with shared protocols. The device also provides quick clinical access of patient data and drag-and-drop screen layouts that can be tailored to clinician preference for individual patient care needs.
Life Scope G9 is patient friendly, featuring a sleep mode that darkens the bedside screen and disables ECG synch sound and alarm indicators for patient comfort. In addition, the Life Scope G9 offers the same reliability of a dedicated ECG machine with its integrated 12-lead ECG capability, minimizing the need to change electrodes and burden the patient with additional stand-alone ECG testing.
“Our goal with the development of the Life Scope G9 is to provide clinicians with a single monitor that will meet their needs, regardless of the situation,” Constantine said. “And with our reputation as the leader in quality and reliability, we believe that the Life Scope G9 will be an essential component in patient care for many hospitals across the nation.”
